Histological research of hepatoprotective activity of tablets Lavaflam in rats with subchronic hepatitis

Abstract

Hepatobiliary system diseases are medical and social problem at the present time. Important issue is the development of a new complex of herbal medicine and its pharmacoeconomic study.The purpose of the work was an experimental substantiation of the hepatoprotective properties of the drug Lavaflam.Methods of research: pharmacological, morphological, histological, methods of mathematical statistics. Materials of research.Experimental pharmacological studies were performed on the white rats weighing 180-220 g. The study was carried out in the Central Research Laboratory (CRL) of the National University of Pharmacy, Kharkіv, Ukraine (Certificate № 023/13 of 05.03.2013) according to the methodological recommendations of the State Expert Center of the Ministry of Health of Ukraine. The rats were divided into four experimental groups: the first group -intact control; the second grouppositive pathology -the animals were injected TChM; the third group -animals, received TChM and Lavaflam; the fourth group -animals, received TChM and reference drug Сarsil.Results. It has been found that the test drug Lavaflam showed hepatoprotective properties in experimental model of the subchronic hepatitis (diffuse inflammatory liver disease) in rats. Conclusions.Lavaflam, in comparison with Carsil contributed to the elimination and reduction in a number of pathological changes, increased adaptive capacity of hepatocytes, and Lavaflam promoted the physiological regeneration of cells. Relating to the effect of a positive influence on the hepatic parenchyma condition with induced subchronic hepatitis by TChM, the drug Lavaflam was not inferior to the comparison drug Carsil (by the effect on necrotic manifestations), or was superior to the comparison drug Carsil (by the zones of destruction spread, dystrophic changes in hepatocytes).